or Try an Advanced Search...

    Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 11.60 -2.11% -0.25
    YMAB closed down 2.11 percent on Friday, May 17, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical YMAB trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New Downtrend Bearish -2.11%
    Calm After Storm Range Contraction -2.11%
    NR7 Range Contraction -2.11%
    Wide Bands Range Expansion -2.11%
    Oversold Stochastic Weakness -2.11%
    Older End-of-Day Signals for YMAB ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    Down 2 % 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    Fell Below Previous Day's Low 2 days ago
    Down 1% 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    YMAB Chart by TradingView
    Basic chart:

    Profile

    Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Cancer Treatment Therapeutic Products Blastoma Brain Tumor Cancer Center Glioma Metastases Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory

    Is YMAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
    May 9 Y-mAbs: There's A Ceiling Here Somewhere
    May 9 Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
    May 9 Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
    May 8 Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript
    May 8 Y-mAbs Therapeutics down 18% as Q1 results disappoint
    May 7 Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates
    May 7 Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
    May 7 Y-mAbs Therapeutics GAAP EPS of -$0.15 in-line, revenue of $19.93M misses by $2.29M
    May 7 Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
    See more YMAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 20.9
    52 Week Low 4.6
    Average Volume 359,454
    200-Day Moving Average 9.60
    50-Day Moving Average 14.96
    20-Day Moving Average 14.49
    10-Day Moving Average 13.29
    Average True Range 1.06
    RSI (14) 30.56
    ADX 26.44
    +DI 14.62
    -DI 32.76
    Chandelier Exit (Long, 3 ATRs) 14.61
    Chandelier Exit (Short, 3 ATRs) 14.67
    Upper Bollinger Bands 18.45
    Lower Bollinger Band 10.53
    Percent B (%b) 0.14
    BandWidth 54.70
    MACD Line -0.92
    MACD Signal Line -0.48
    MACD Histogram -0.44
    Fundamentals Value
    Market Cap 506.01 Million
    Num Shares 43.6 Million
    EPS -0.45
    Price-to-Earnings (P/E) Ratio -25.78
    Price-to-Sales 6.16
    Price-to-Book 5.71
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.38
    Resistance 3 (R3) 12.43 12.23 12.25
    Resistance 2 (R2) 12.23 12.03 12.20 12.21
    Resistance 1 (R1) 11.91 11.91 11.81 11.86 12.16
    Pivot Point 11.71 11.71 11.66 11.68 11.71
    Support 1 (S1) 11.39 11.51 11.29 11.34 11.04
    Support 2 (S2) 11.19 11.39 11.16 10.99
    Support 3 (S3) 10.87 11.19 10.95
    Support 4 (S4) 10.82